Stock Screener App

Gratuito -

Installare

20.15

2.78% 0.54

Amphastar Pharmaceuticals Inc (AMPH)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché AMPH Giù? Forum Previsione

Amphastar Pharmaceuticals Inc Borsa (AMPH) Ultime notizie

Price to earnings forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH - TradingView

Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH - TradingView

Crude Oil Gains 2%; Comcast Shares Spike Higher - Sahm

Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com

Enterprise value to EBIT forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH - TradingView

Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2500 Growth Benchmark - marketscreener.com

Amphastar Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $22, Implies 1% Upside - TradingView

AMPH Downgraded by B of A Securities -- Price Target Lowered to $20 - GuruFocus

BofA cuts Amphastar stock rating on limited growth visibility By Investing.com - Investing.com Canada

Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Growth Benchmark - marketscreener.com

BofA Securities Downgrades Amphastar Pharmaceuticals(AMPH.US) to Sell Rating, Cuts Target Price to $20 - Moomoo

This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Sahm

Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. – LS:A11664 - TradingView

Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Growth-Defensive Index - marketscreener.com

Amphastar Pharmaceuticals, Inc.(NasdaqGS: AMPH) added to Russell 2000 Dynamic Index - marketscreener.com

Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. – GETTEX:29A - TradingView

Price to book forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH - TradingView

Price to sales forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH - TradingView

Price to earnings forward of Amphastar Pharmaceuticals, Inc. – LS:A11664 - TradingView

Amphastar Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMPH) - TradingView

AMPH Forecast — Price Target — Prediction for 2027 - TradingView

Amphastar Pharmaceuticals Inc (AMPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Price-Driven Insight from (AMPH) for Rule-Based Strategy - Stock Traders Daily

Over-the-Counter Rextovy Cleared for Opioid Overdose Treatment - Clinical Pain Advisor

Amphastar Pharmaceuticals Inc (AMPH) Institutional Confidence - TradingKey

Amphastar Pharmaceuticals Inc (AMPH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

AMPH Technical Analysis & Stock Price Forecast - Intellectia AI

Amphastar Pharmaceuticals Inc (AMPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Amphastar Pharmaceuticals Inc (AMPH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Amphastar Pharmaceuticals Inc - TradingKey

Amphastar Pharmaceuticals Inc (AMPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Amphastar Pharmaceuticals Inc (AMPH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Amphastar Pharmaceuticals Inc (AMPH) Valuation: PE, PB & Fair Value Analysis - TradingKey

Naloxone Nasal Spray Gets Third OTC Brand as FDA Approves Rextovy by Amphastar - Tech Times

Third US OTC Approval In Three Weeks Goes To Amphastar’s Naloxone Spray - insights.citeline.com

Amphastar Pharmaceuticals (AMPH) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Challenging QuarterFull Year Guidance - newsline.com

(AMPH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Healthcare Stock Picks: RadNet and Amphastar to Sell, One Stock to Watch | June 2026News and Statistics - IndexBox

Amphastar Pharmaceuticals pivots to proprietary drugs, biosimilars for growth - MSN

Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth - MarketBeat

How The Investment Story For Amphastar Pharmaceuticals (AMPH) Is Evolving Without New Valuation Shifts - Yahoo Finance

Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged - GlobeNewswire

Amphastar Pharmaceuticals sees generic Atrovent fueling 2026 growth despite BAQSIMI drag - MSN

Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $20 - Moomoo

Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag - MarketBeat

Amphastar (AMPH) director awarded RSUs and options with tax withholding update - Stock Titan

Amphastar Pharmaceuticals (AMPH) director receives RSUs and options grant - Stock Titan

Deflin Gayle awarded RSUs and stock options at Amphastar (NASDAQ: AMPH) - Stock Titan

Amphastar (AMPH) director Diane Gerst receives RSUs and stock option grant - Stock Titan

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha

Amphastar (AMPH) holders approve directors, EY auditor and annual say-on-pay - Stock Titan

Amphastar Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Gerst Diane G. - Moomoo

(AMPH) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty - Yahoo Finance

Amphastar (AMPH) Q1 2026 Earnings Transcript - AOL.com

Amphastar Pharmaceuticals (AMPH) Gains 1.4% as Stock Tests Resistance Near $20.34Retail Sentiment - newsline.com

Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference - ACCESS Newswire

AMPHAmphastar Pharmaceuticals Inc Stock Price and Quote - Finviz

(AMPH) Risk Channels and Responsive Allocation - Stock Traders Daily

Amphastar Pharmaceuticals (AMPH) Shows Modest Gains as Stock Hovers Near Key ResistanceQuality Factor - The Legal Advocate

ALKS

$54.74

0.71%

RDY

$14.69

2.30%

ELAN

$24.53

2.35%

NBIX

$175.34

0.86%

VTRS

$17.00

1.16%

UTHR

$557.75

1.78%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters